In breast cancer, legumain fosters tumor cell proliferation and metastasis, while in glioblastoma, it is implicated in the inactivation of the tumor suppressor protein p53 and the cleavage of tropomodulin-3, contributing to cellular and genetic destabilization. This evidence concerns the gene TMOD3 and breast cancer.